0000835662 true 0000835662 2021-05-25 2021-05-25 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K/A

(Amendment No. 1)

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(D) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (date of earlies event reported): May 25, 2021

 

 

 

AIXIN LIFE INTERNATIONAL, INC.

(Exact name of registrant as specified in its charter)

 

Colorado   0-17284   84-1085935
State of   Commission   IRS Employer
Incorporation   File Number   Identification No.

 

Hongxing International Business Building 2, 14th FL, No. 69 Qingyun South Ave., Jinjiang District

Chengdu City, Sichuan Province, China

(Address of principal executive offices)

 

86-313-6732526

(Issuer’s telephone number)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock   AIXN   OTCQX

 

 

 

 

 

 

Cautionary Note Regarding Forward-Looking Statements:

 

Any statements contained in this Current Report on Form 8-K that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are generally identifiable by use of the words “believes,” “expects,” “intends,” “anticipates,” “plans to,” “estimates,” “projects,” or similar expressions. Such statements may include, but are not limited to, statements about the Registrant’s planned acquisitions, the purchase price to be paid for such acquisitions and the future performance of the businesses to be acquired, and other statements that are not historical facts. Such statements are based upon the beliefs and expectations of the Company’s management as of this date only and are subject to risks and uncertainties that could cause actual results to differ materially. Therefore, investors are cautioned not to place undue reliance on these forward-looking statements. The Company undertakes no obligation to revise or publicly release the results of any revision to these forward-looking statements, whether as a result of new information, future events or otherwise, other than as required by applicable law.

 

Explanatory Note

 

We filed a Report on Form 8-K dated May 25, 2021 (the “May 25 8-K”), with respect to the acquisition of Chengdu Aixin Shangyan Hotel Management Co., Ltd. (“Shangyan Co”) which owns and operates a hotel located in the Jinniu District, Chengdu City. The May 25 8-K, as previously amended, included the historical financial information of Shangyan Co for the years ended December 31, 2020 and 2019, and the three months ended March 31, 2021.

 

We filed an additional Report on Form 8-K dated June 2, 2021 (the “June 2 8-K”), with respect to the acquisition of Chengdu Aixintang Pharmacy Co., Ltd. and its affiliated entities (collectively, “Pharmacy Co”) which also are being acquired by us. The June 2 8-K, as previously amended, included the historical financial information of Pharmacy Co for the years ended December 31, 2020 and 2019, and the three months ended March 31, 2021.

 

This Form 8-K/A is being filed to include the historical financial information of each of Shangyan Co and Pharmacy Co for the three and six month periods ended June 30, 2021, and pro forma financial information as of June 30, 2021, showing the combined effects of the acquisitions of Shangyan Co and Pharmacy Co as required by Item 9.01 of Form 8-K. This Form 8-K/A makes no other amendments to the May 25 8-K and the June 2 8-K and should be read in conjunction with such Reports.

 

 

 

 

Item 9.01 Financial Statements and Exhibits.

 

(a) Financial statements of business acquired.

 

The unaudited combined balance sheets of Chengdu Aixin Shangyan Hotel Management Co., Ltd. (“Shangyan Co”) as of June 30, 2021 and the related unaudited combined statements of operations and comprehensive loss, changes in equity (deficit) and cash flows for the three and six months ended June 30, 2021 and the related notes to the unaudited combined financial statements, is filed as Exhibit 99.2 to this Current Report on Form 8-K/A and incorporated herein by reference.

 

The unaudited balance sheets of Chengdu Aixintang Pharmacy Co., Ltd. and its affiliates (collectively, “Pharmacy Co”) as of June 30, 2021, and the related combined statements of operations and comprehensive loss, changes in equity (deficit), and cash flows for the three and six months then ended and the related notes to the financial statements, are filed as Exhibit 99.4 to this Current Report on Form 8-K/A and incorporated herein by reference.

 

(b) Pro forma financial information

 

The unaudited pro forma condensed combined financial statements annexed hereto as Exhibit 99.5 combines the historical balance sheets of Aixin Life International, Inc., Hotel Co and Pharmacy Co as if the acquisitions of Shangyan Co and Pharmacy Co (the “Transactions”) had occurred on June 30, 2021. The unaudited pro forma combined statements of operations and comprehensive loss for the six months ended June 30, 2021 and for the year ended December 31, 2020 combine the historical consolidated statements of operations and comprehensive income (loss) of Aixin Life International, Inc., Shangyan Co and Pharmacy Co, and have been prepared as if the Transactions had closed on January 1, 2020, respectively. The unaudited pro forma condensed combined financial statements have also been adjusted to give effect to pro forma events that are directly attributable to the Transactions, factually supportable and expected to have a continuing impact on the combined results.

 

(c) Exhibits:

 

  Exhibit No.   Description
       
  23.1   Consent of KCCW Accountancy Corp., independent registered public accounting firm
       
  23.2   Consent of KCCW Accountancy Corp., independent registered public accounting firm
       
  99.1   Audited Financial Statements of Aixin Shangyan Hotel Management Co., Ltd. as of and for the years ended December 31, 2020 and 2019. (Incorporated by reference to Report on Form 8-K/A filed August 16, 2021).
       
  99.2   Unaudited Combined Financial Statements of Chengdu Aixin Shangyan Hotel Management Co., Ltd. as of June 30, 2021, and for the three and six months ended June 30, 2021.
       
  99.3   Audited Financial Statements of Chengdu Aixintang Pharmacy Co. Ltd. as of and for the years ended December 31, 2020 and 2019. (Incorporated by reference to Report on Form 8-K/A filed August 17, 2021).
       
  99.4   Unaudited Combined Financial Statements of Chengdu Aixintang Pharmacy Co., Ltd. as of June 30, 2021, and for the three and six months ended June 30, 2021.
       
  99.5   Unaudited Pro Forma Combined Financial Statements as of June 30, 2021, and for the six months ended June 30, 2021.
       
  104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  AiXin Life International, Inc.
     
Date: October 14, 2021 By: /s/ Quanzhong Lin
    Quanzhong Lin
    Chief Executive Officer

 

 

 

Exhibit 23.1

 

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

We hereby consent to the inclusion, in this Form 8-K/A, of our report, dated August 12, 2021, with respect to our audit on the financial statements of Chengdu Aixin Shangyan Hotel Management Co., Ltd. for the years ended December 31, 2020 and 2019.

 

KCCW Accountancy Corp.

Diamond Bar, California

October 14, 2021

 

 

 

Exhibit 23.2

 

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

We hereby consent to the inclusion, in this Form 8-K/A, of our report, dated August 12, 2021, with respect to our audit on the combined financial statements of Chengdu Aixintang Pharmacy Co., Ltd. for the years ended December 31, 2020 and 2019.

 

KCCW Accountancy Corp.

Diamond Bar, California

October 14, 2021

 

 

 

 

Exhibit 99.2

 

CHENGDU AIXIN SHANGYAN HOTEL MANAGEMENT CO., LTD.

BALANCE SHEETS

 

    June 30,     December 31,  
    2021     2020  
      (Unaudited)          
ASSETS                
CURRENT ASSETS                
Cash and cash equivalents     19,039       512  
Accounts receivable, net     27,163       16,189  
Accounts receivable, related party     6,020       60,262  
Other receivables     40,050       45,160  
Prepaid expenses     65,229       102,715  
Inventory, net     184,739       52,642  
Prepaid taxes     -       7,090  
Total current assets     342,240       284,570  
NON-CURRENT ASSETS                
Property and equipment, net     309,883       321,587  
Intangible assets, net     3,213       4,465  
Security deposits     92,928       91,954  
Operating lease right-of-use assets     1,684,168       2,007,370  
Total non-current assets     2,090,192       2,425,376  
TOTAL ASSETS   $ 2,432,432     $ 2,709,946  
                 
LIABILITIES AND STOCKHOLDERS’ DEFICIT                
CURRENT LIABILITIES                
Accounts payable     284,498       25,378  
Deferred revenue     293,857       283,974  
Accrued liabilities and other payables     246,129       292,251  
Taxes payable     4,138       -  
Loans from third parties     462,282       457,436  
Operating lease liabilities - current     639,726       623,607  
Due to related parties     1,427,206       1,115,326  
Total current liabilities     3,357,836       2,797,972  
NON-CURRENT LIABILITIES                
Operating lease liabilities - non-current     1,044,442       1,383,763  
Total non-current liabilities     1,044,442       1,383,763  
TOTAL LIABILITIES     4,402,278       4,181,735  
                 
STOCKHOLDERS’ DEFICIT                
Paid-in capital     152,207       152,207  
Accumulated deficit     (2,033,012 )     (1,551,559 )
Accumulated other comprehensive loss     (89,041 )     (72,437 )
Total stockholders’ deficit     (1,969,846 )     (1,471,789 )
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT   $ 2,432,432     $ 2,709,946  

 

 

 

 

CHENGDU AIXIN SHANGYAN HOTEL MANAGEMENT CO., LTD.

STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(UNAUDITED)

 

    For the Three Months Ended June 30,     For the Six Months Ended June 30,  
    2021     2020     2021     2020  
Revenues   $ 395,809     $ 183,088     $ 748,056     $ 359,962  
                                 
Operating costs and expenses:                                
Hotel operating costs     525,346       397,902       1,043,851       717,273  
Selling and marketing expenses     2,604       632       74,189       4,233  
General and administrative expenses     55,871       31,462       138,071       58,033  
Provision for bad debts     25,967       837       25,967       15,177  
Total operating costs and expenses     609,788       430,833       1,282,078       794,716  
                                 
Loss from operations     (213,979 )     (247,745 )     (534,022 )     (434,754 )
                                 
Other income                                
Other income     30,766       14,348       52,548       8,212  
Interest income     13       3       21       10  
Total other income     30,779       14,351       52,569       8,222  
                                 
Loss before income tax     (183,200 )     (233,394 )     (481,453 )     (426,532 )
Income tax expense     -       -       -       -  
Net loss     (183,200 )     (233,394 )     (481,453 )     (426,532 )
                                 
Other comprehensive items                                
Foreign currency translation income (loss)     (25,816 )     (2,496 )     (16,604 )     12,163  
Comprehensive loss   $ (209,016 )   $ (235,890 )   $ (498,057 )   $ (414,369 )

 

 

 

 

CHENGDU AIXIN SHANGYAN HOTEL MANAGEMENT CO., LTD.

STATEMENTS OF CHANGES IN EQUITY

(UNAUDITED)

 

                Accumulated        
          Accumulated     other comprehensive        
    Paid-in Capital     Deficit     income (loss)     Total  
                         
Balance at December 31, 2020   $ 152,207     $ (1,551,559 )   $ (72,437 )   $ (1,471,789 )
Net loss     -       (298,253 )     -       (298,253 )
Foreign currency translation     -       -       9,212       9,212  
Balance at March 31, 2021     152,207       (1,849,812 )     (63,225 )     (1,760,830 )
Net loss     -       (183,200 )     -       (183,200 )
Foreign currency translation     -       -       (25,816 )     (25,816 )
Balance at June 30, 2021   $ 152,207     $ (2,033,012 )   $ (89,041 )   $ (1,969,846 )

 

                Accumulated        
          Accumulated     other comprehensive        
    Paid-in Capital     Deficit     income (loss)     Total  
Balance at December 31, 2019   $ 152,207     $ (862,454 )   $ 14,205     $ (696,042 )
Net loss     -       (193,138 )     -       (193,138 )
Foreign currency translation     -       -       14,659       14,659  
Balance at March 31, 2020     152,207       (1,055,592 )     28,864       (874,521 )
Net loss     -       (233,394 )     -       (233,394 )
Foreign currency translation     -       -       (2,496 )     (2,496 )
Balance at June 30, 2020   $ 152,207     $ (1,288,986 )   $ 26,368     $ (1,110,411 )

 

 

 

 

CHENGDU AIXIN SHANGYAN HOTEL MANAGEMENT CO., LTD.

STATEMENTS OF CASH FLOWS

(UNAUDITED)

 

    For the Six Months Ended June 30,  
    2021     2020  
Cash flows from operating activities                
Net loss   $ (481,453 )   $ (426,532 )
Adjustments to reconcile net loss to net cash used in operating activities:                
Depreciation and amortization     18,564       14,031  
Provision for bad debts     25,967       15,177  
Changes in assets and liabilities:                
Accounts receivable     (36,746 )     76,032  
Other receivables     5,577       (22,550 )
Inventory     (131,264 )     (5,811 )
Prepaid expenses     38,492       18,207  
Accounts payable     258,308       (20,670 )
Accrued expenses and other payables     (49,115 )     125,750  
Taxes Payable     11,280       (16,032 )
Deferred revenue     6,860       27,931  
Net cash used in operating activities     (333,530 )     (214,467 )
                 
Cash flows from investing activities                
Purchase of equipment     (2,190 )     (1,400 )
Net cash used in investing activities     (2,190 )     (1,400 )
                 
Cash flows from financing activities                
Net proceeds from related parties     354,200       166,921  
Net cash provided by financing activities     354,200       166,921  
                 
Effect of exchange rate changes on cash and cash equivalents     47       (548 )
                 
NET INCREASE (DECREASE) IN CASH AND EQUIVALENTS     18,527       (49,494 )
                 
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD     512       53,059  
                 
CASH AND CASH EQUIVALENTS, END OF PERIOD   $ 19,039     $ 3,565  
                 
Supplemental cash flow data:                
Income tax paid   $ -     $ -  
Interest paid   $ -     $ -  

 

 

 

 

CHENGDU AIXIN SHANGYAN HOTEL MANAGEMENT CO., LTD.

NOTES TO FINANCIAL STATEMENTS

(UNAUDTIED)

 

1. ORGANIZATION AND DESCRIPTION OF BUSINESS

 

Chengdu Aixin Shangyan Hotel Management Co., Ltd. (the “Company” or “Shangyan Hotel”) was incorporated in 2016 in Chengdu, China. Shangyan Hotel is a four-star hotel, covering an area of more than 8,000 square meters. It is equipped with full central air-conditioning, a large restaurant that can accommodate 600 people at the same time, 6 luxurious dining rooms, 200 square meters of music tea house, 13 tea private rooms, 108 guest rooms and other supporting facilities.

 

Shangyan hotel is located at superior geographical position and a 5-minute drive from Wal-Mart, CapitaLand and other large shopping malls; The hotel has convenient transportation, which is connected to the express ring line and the bus system, and it takes 30-minute drive to Chengdu Shuangliu International Airport.

 

On May 25, 2021, the Company’s two shareholders, Quanzhong Lin and Yirong Shen, of which Quanzhong Lin is also the Chairman and President and major shareholder of Aixin Life International, Inc. (“Aixin Life”), entered into an Equity Transfer Agreement with Aixin Life. Pursuant to the Agreement (the “Hotel Purchase Agreement”), Aixin Life agreed to purchase 100% ownership of Shangyan Hotel from Mr. Lin and Ms. Shen. Eighty percent of the equity of Shangyan Hotel is owned by Mr. Lin, and the remaining twenty percent is owned by Ms. Shen. Under the terms of the Hotel Purchase Agreement, Aixin Life agreed to purchase all of the outstanding equity of Shangyan Hotel for a purchase price of RMB 7,598,887 or US$1,164,598 based on an exchange rate of RMB / US$ 6.5249 yuan per dollar on December 31, 2020. The purchase price will be reduced by an amount equal to any amounts paid or distributed by Shangyan Hotel to Mr. Lin or Ms. Shen after December 31, 2020 and will be increased by an amount equal to any amounts they contributed to Shangyan Hotel after December 31, 2020.

 

As of June 30, 2021, the governmental procedures to complete the equity transfer of Shangyan Hotel were not yet completed (see Note 14).

 

Both Aixin Life and Shangyan Hotel are under common control and ownership.

 

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of Presentation

 

The accompanying financial statements are prepared in conformity with U.S. Generally Accepted Accounting Principles (“US GAAP”). The functional currency of the Company is Chinese Renminbi (“RMB”). The accompanying financial statements are translated from RMB and presented in U.S. dollars (“USD”).

 

Covid – 19

 

On March 11, 2020, the World Health Organization announced that infections caused by the corona virus disease of 2019 (“COVID-19”) had become pandemic. The Government of China has adopted various regulations and orders, including mandatory quarantines, limits on the number of people that may gather in one location, closing non-essential businesses and travel bans to limit the spread of the disease. COVID-19 and measures to prevent its spread impacted the Company’s operations, most significantly at hotel rooms and restaurant which were closed or operating at significantly reduced capacity for a significant portion during the year 2020. However, many of these measures have been relaxed due to the decrease in the prevalence of Covid-19 in China. During the three and six months ended June 30, 2021, the ongoing operations of the Company have been back to normal.

 

Financial impacts related to COVID-19 were not material to the Company’s financial position, results of operations or cash flows for the three and six months ended June 30, 2021. The Company has implemented procedures to promote employee and customer safety. These measures did not significantly increase its operating costs.

 

 

 

 

While the Company continues to operate substantially in the normal course, it cannot forecast with any certainty whether and to what degree the disruptions caused by the COVID-19 pandemic will increase, or the extent to which the disruption may materially impact its financial position, results of operations, and cash flows in fiscal 2021.

 

Use of Estimates

 

In preparing financial statements in conformity with US GAAP, management makes estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the dates of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period.

 

Significant estimates, required by management, include the recoverability of long-lived assets, allowance for doubtful accounts, and the reserve for obsolete and slow-moving inventories. Actual results could differ from those estimates.

 

Cash and Cash Equivalents

 

For financial statement purposes, the Company considers all highly liquid investments with an original maturity of three months or less to be cash and cash equivalents.

 

Accounts Receivable

 

Accounts receivable mainly consist of amounts due from corporate customers, travel agents, and hotel guests. The Company’s policy is to maintain an allowance for potential credit losses on accounts receivable. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentrations, customer credit worthiness, current economic trends and changes in customer payment patterns to evaluate the adequacy of these reserves. As of June 30, 2021 and December 31, 2020, the allowance for doubtful accounts was $50,638 and $24,359, respectively.

 

Inventory

 

Inventory mainly consists of food and beverage, hotel supplies, and consumables. Inventory is valued at the lower of average cost or market, cost being determined on a moving weighted average method at the end of the month. Management compares the cost of inventories with the net realizable value and an allowance is made for writing down inventories to market value, if lower. The Company recorded no inventory impairment for the three and six months ended June 30, 2021 and 2020.

 

In July 2015, the FASB issued Accounting Standards Update (“ASU”) 2015-11, “Inventory (Topic 330) - Simplifying the Measurement of Inventory,” which requires that inventory within the scope of the guidance be measured at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation.

 

Property and Equipment

 

Property and equipment are stated at cost, less accumulated depreciation, and impairment losses, if any. Major repairs and betterments that significantly extend original useful lives or improve productivity are capitalized and depreciated over the period benefited. Maintenance and repairs are expensed as incurred. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of property and equipment is provided using the straight-line method for substantially all assets with 5% salvage value and estimated lives as follows:

 

Machinery 3 years
Electronic Equipment 3 years

 

 

 

 

Impairment of Long-Lived Assets

 

Long-lived assets, which include property and equipment and intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable, but at least annually.

 

Recoverability of long-lived assets to be held and used is measured by comparing the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by it. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds its fair value. Fair value is generally determined using the asset’s expected future discounted cash flows or market value, if readily determinable. Based on its review, the Company believes that, as of June 30, 2021 and December 31, 2020, there were no significant impairments of its long-lived assets.

 

Income Taxes

 

Income taxes are accounted for using an asset and liability method. Under this method, deferred income taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts at each period end based on enacted tax laws and statutory tax rates, applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.

 

The Company follows Accounting Standards Codification (“ASC”) Topic 740, which prescribes a more-likely-than-not threshold for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. ASC Topic 740 also provides guidance on recognition of income tax assets and liabilities, classification of current and deferred income tax assets and liabilities, accounting for interest and penalties associated with tax positions, accounting for income taxes in interim periods, and income tax disclosures.

 

Under ASC Topic 740, when tax returns are filed, it is likely that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained. The benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50% likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described above is reflected as a liability for unrecognized tax benefits in the accompanying balance sheets along with any associated interest and penalties that would be payable to the taxing authorities upon examination. Interest associated with unrecognized tax benefits is classified as interest expense and penalties are classified in selling, general and administrative expenses in the statement of operations.

 

At June 30, 2021 and December 31, 2020, the Company did not take any uncertain positions that would necessitate recording a tax related liability.

 

Revenue Recognition

 

In accordance with ASC 606, revenue is recognized upon the transfer of control of promised goods or services to customers in an amount that reflects the consideration the Company expects to receive in exchange for those products or services.

 

Revenue from sale of goods and services under Topic 606 is recognized in a manner that reasonably reflects the delivery of the Company’s products and services to customers in return for expected consideration and includes the following elements:

 

  executed contract(s) with customers that the Company believes is legally enforceable;

 

  identification of performance obligation in the respective contract;

 

 

 

 

  determination of the transaction price for each performance obligation in the respective contract;
     
   allocation of the transaction price to each performance obligation; and
     
   recognition of revenue only when the Company satisfies each performance obligation.

 

Revenues are primarily derived from the rental of rooms, food and beverage sales and other ancillary goods and services, including but not limited to souvenir, parking and conference reservation. Each of these products and services represents a distinct performance obligation and, in exchange for these services, the Company receives fixed amounts based on published rates or negotiated contracts. Payment is due in full at the time when the services are rendered or the goods are provided. Room rental revenue is recognized on a daily basis when rooms are occupied. Food and beverage revenue and other goods and services revenue are recognized when they have been delivered or rendered to the guests as the respective performance obligations are satisfied.

 

The Company generally receives payments from customers as its performance obligations were satisfied. The Company records a receivable when it has an unconditional right to receive payment and only the passage of time is required before payment is due. The Company records deferred revenue when it receives cash proceeds in advance of the satisfaction of respective performance obligations related to accommodations and other ancillary services.

 

Sales revenue represents the invoiced value of goods, net of value-added taxes (“VAT”). All of the Company’s goods sold in China are subject to the PRC VAT of 6%. This VAT may be offset by VAT paid by the Company on raw materials and other materials purchased in China. The Company records VAT payable and VAT receivable net of payments in the financial statements. The VAT tax return is filed offsetting the payables against the receivables. Sales and purchases are recorded net of VAT collected and paid as the Company acts as an agent for the government.

 

Disaggregated Revenues

 

The following tables present the Company’s revenues disaggregated by the nature of the product or service:

 

   

For the Three Months

Ended June 30,

 
    2021     2020  
Room revenues   $ 179,780     $ 91,354  
Food and beverage revenues     175,494       66,668  
Others     40,535       25,066  
Total revenues   $ 395,809     $ 183,088  

 

   

For the Six Months

Ended June 30,

 
    2021     2020  
Room revenues   $ 330,559     $ 166,906  
Food and beverage revenues     344,131       147,043  
Others     73,366       46,013  
Total revenues   $ 748,056     $ 359,962  

 

Concentration of Credit Risk

 

The operations of the Company are in the PRC. Accordingly, the Company’s business, financial condition, and results of operations may be influenced by the political, economic, and legal environments in the PRC, and by the general state of the PRC economy.

 

 

 

 

The Company has cash on hand and demand deposits in accounts maintained with state-owned banks within the PRC. Cash in state-owned banks is covered by insurance up to RMB 500,000 ($72,500) per bank. The Company has not experienced any losses in such accounts and believes they are not exposed to any risks on its cash in these bank accounts.

 

Leases

 

The Company adopted FASB Accounting Standards Codification, Topic 842, Leases (“ASC 842”) using the modified retrospective approach, electing the practical expedient that allows the Company not to restate the periods prior to the adoption of the standard on January 1, 2019.

 

The Company applied the following practical expedients in the transition to the new standard allowed under ASC 842:

 

Practical Expedient   Description
Reassessment of expired or existing contracts   The Company elected not to reassess, at the application date, whether any expired or existing contracts contained leases, the lease classification for any expired or existing leases, and the accounting for initial direct costs for any existing leases.
Use of hindsight   The Company elected to use hindsight in determining the lease term (that is, when considering options to extend or terminate the lease and to purchase the underlying asset) and in assessing impairment of right-to-use assets.
Reassessment of existing or expired land easements   The Company elected not to evaluate existing or expired land easements that were not previously accounted for as leases under ASC 840, as allowed under the transition practical expedient. Going forward, new or modified land easements will be evaluated under ASU No. 2016-02.
Separation of lease and non-lease components   Lease agreements that contain both lease and non-lease components are generally accounted for separately.
Short-term lease recognition exemption   The Company also elected the short-term lease recognition exemption and will not recognize ROU assets or lease liabilities for leases with a term less than 12 months.

 

The new leasing standard requires recognition of leases on the balance sheets as right-of-use (“ROU”) assets and lease liabilities. ROU assets represent the Company’s right to use underlying assets for the lease terms and lease liabilities represent the Company’s obligation to make lease payments arising from the leases. Operating lease ROU assets and operating lease liabilities are recognized based on the present value and future minimum lease payments over the lease term at commencement date. The Company’s future minimum based payments used to determine the Company’s lease liabilities mainly include minimum based rent payments. As most of the Company’s leases do not provide an implicit rate, the Company uses its estimated incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments.

 

The most significant impact on the adoption of ASC 842 was the recognition of the operating lease right-of-use assets and the liabilities for operating leases on its balance sheets. Accordingly, adoption of this standard resulted in the recognition of operating lease right-of-use assets of $2,932,536 and operating lease liabilities of $2,932,536 on the balance sheet as of January 1, 2019. The adoption of ASC 842 did not result in a cumulative-effect adjustment to the opening balance of retained earnings (accumulated deficit).

 

In addition, the adoption of the standard did not have a material impact on the Company’s results of operations or cash flows. Operating lease cost is recognized as a single lease cost on a straight-line basis over the lease term and is recorded in selling, general and administrative expenses. Variable lease payments for common area maintenance, property taxes and other operating expenses are recognized as expense in the period when the changes in facts and circumstances on which the variable lease payments are based occur.

 

Statement of Cash Flows

 

In accordance with ASC Topic 230, “Statement of Cash Flows,” cash flows from the Company’s operations are calculated based on the local currencies using the average translation rates. As a result, amounts related to assets and liabilities reported on the statements of cash flows will not necessarily agree with changes in the corresponding balances on the balance sheets.

 

 

 

 

Fair Value of Financial Instruments

 

The carrying amounts of certain of the Company’s financial instruments, including cash and equivalents, accrued liabilities and accounts payable, approximate their fair value due to their short maturities. FASB ASC Topic 825, “Financial Instruments,” requires disclosure of the fair value of financial instruments held by the Company. The carrying amounts reported in the balance sheets for current liabilities each qualify as financial instruments and are a reasonable estimate of their fair value because of the short period of time between the origination of such instruments and their expected realization and the current market rate of interest.

 

Fair Value Measurements and Disclosures

 

ASC Topic 820, “Fair Value Measurements and Disclosures,” defines fair value, and establishes a three-level valuation hierarchy for disclosures of fair value measurement that enhances disclosure requirements for fair value measures. The three levels are defined as follow:

 

  Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.
  Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.
  Level 3 inputs to the valuation methodology are unobservable and significant to the fair value measurement.

 

As of June 30, 2021 and December 31, 2020, the Company did not identify any assets and liabilities that are required to be presented on the balance sheet at fair value.

 

Foreign Currency Translation and Comprehensive Income (Loss)

 

The functional currency of the Company is RMB. For financial reporting purposes, RMB is translated into USD as the reporting currency. Assets and liabilities are translated at the exchange rate in effect at the balance sheet dates. Revenues and expenses are translated at the average rate of exchange prevailing during the reporting period.

 

Translation adjustments arising from the use of different exchange rates from period to period are included as a component of stockholders’ equity as “Accumulated other comprehensive income”. Gains and losses resulting from foreign currency transactions are included in income. There was no significant fluctuation in the exchange rate for the conversion of RMB to USD after the balance sheet date.

 

The Company uses FASB ASC Topic 220, “Comprehensive Income”. Comprehensive loss is comprised of net loss and all changes to the statements of stockholders’ equity, except those due to investments by stockholders, changes in paid-in capital and distributions to stockholders. Comprehensive income (loss) for the three and six months ended June 30, 2021 and 2020 consisted of net income (loss) and foreign currency translation adjustments.

 

Earnings per Share

 

The Company is a limited Company (“LC”) formed under the laws of the PRC. Like limited liability company in the US, limited company in the PRC do not issue shares to the owners. The owners however, are called shareholders. Ownership interest is determined in proportion to capital contributed. Accordingly, earnings per share data is not presented.

 

Segment Reporting

 

ASC Topic 280, “Segment Reporting,” requires use of the “management approach” model for segment reporting. The management approach model is based on the way a company’s chief operating decision maker organizes segments within the Company for making operating decisions assessing performance and allocating resources. Reportable segments are based on products and services, geography, legal structure, management structure, or any other manner in which management disaggregates a company.

 

 

 

 

Management determined the Company’s operations constitute a single reportable segment in accordance with ASC 280. The Company operates exclusively in one business and industry segment: hospitality.

 

New Accounting Pronouncements

 

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326), which requires entities to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. This replaces the existing incurred loss model and is applicable to the measurement of credit losses on financial assets measured at amortized cost. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2022. Early application will be permitted for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. The Company is currently evaluating the impact that the standard will have on its financial statements.

 

In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848) (“ASU 2020-04”). ASU 2020-04 contains practical expedients for reference rate reform related activities that impact debt, leases, derivatives and other contracts. The guidance in ASU 2020-04 is optional and may be elected over time as reference rate reform activities occur. The Company continues to evaluate the impact of the guidance and may apply the elections as applicable as changes in the market occur.

 

3. PREPAID EXPENSES

 

The Company had prepaid expenses of $65,229 and $102,715 as of June 30, 2021 and December 31, 2020, respectively. Prepaid expenses primarily consist of prepaid consulting fee and other expenses.

 

4. INVENTORY

 

Inventory consisted of the following at June 30, 2021 and December 31, 2020:

 

   

June 30,

2021

   

December 31,

2020

 
Food and beverage, supplies, and consumables   $ 184,739     $ 52,642  

 

5. PROPERTY AND EQUIPMENT, NET

 

Property and equipment consisted of the following at June 30, 2021 and December 31, 2020:

 

   

June 30,

2021

    December 31,
2020
 
Machinery   $ 103,535     $ 101,629  
Electronic equipment     6,826       6,754  
Other     6,291       4,874  
Construction in progress     253,210       250,556  
Total     369,862       363,813  
Less: Accumulated depreciation     (59,979 )     (42,226 )
Property and equipment, net   $ 309,883     $ 321,587  

 

Depreciation expense for the three months ended June 30, 2021 and 2020 was $8,822 and $6,487, respectively. Depreciation expense for the six months ended June 30, 2021 and 2020 was $17,268 and $12,898, respectively.

 

 

 

 

6. INTANGIBLE ASSETS, NET

 

Intangible assets consisted of the following at June 30, 2021 and December 31, 2020:

 

   

June 30,

2021

   

December 31,

2020

 
Software   $ 7,793     $ 7,711  
Less: Accumulated amortization     (4,580 )     (3,246 )
Intangible assets, net   $ 3,213     $ 4,465  

 

Amortization expense for the three months ended June 30, 2021 and 2020 was $649 and $562, respectively.

 

Amortization expense for the six months ended June 30, 2021 and 2020 was $1,296 and $1,133, respectively.

 

7. ACCRUED LIABILITIES AND OTHER PAYABLES

 

Accrued liabilities and other payables consisted of the following at June 30, 2021 and December 31, 2020:

 

   

June 30,

2021

   

December 31,

2020

 
Accrued payroll   $ 32,828     $ 57,616  
Construction payables     77,538       96,844  
Accrued rent     88,910       112,500  
Other payables     46,853       25,291  
Total   $ 246,129     $ 292,251  

 

8. LOAN FROM THIRD PARTIES

 

As of June 30, 2021 and December 31, 2020, the Company had advances from former shareholders and unrelated third parties in an aggregate amount of $462,282 and $457,436, respectively. There was no written agreement, and these loans are payable on demand and bear no interest.

 

9. LEASE

 

The Company leased its hotel premises under an operating lease arrangement. The lease has a remaining lease term of approximately 2.5 years.

 

Balance sheet information related to the Company’s leases is presented below:

 

   

June 30,

2021

   

December 31,

2020

 
Operating Leases                
Operating lease right-of-use assets   $ 1,684,168     $ 2,007,370  
                 
Operating lease liabilities - current   $ 639,726     $ 623,607  
Operating lease liability – non-current     1,044,442       1,383,763  
Total operating lease liabilities   $ 1,684,168     $ 2,007,370  

 

The following provides details of the Company’s lease expenses:

 

    Three Months Ended June 30,  
    2021     2020  
Operating lease expenses   $ 170,256     $ 158,327  

 

    Six Months Ended June 30,  
    2021     2020  
Operating lease expenses   $ 346,821     $ 319,104  

 

 

 

 

Other information related to leases is presented below:

 

    Six Months Ended June 30,  
    2021     2020  
Cash Paid For Amounts Included In Measurement of Liabilities:            
Operating cash flows from operating leases   $ 346,821     $ 319,104  
                 
Weighted Average Remaining Lease Term:                
Operating leases     2.50 years       3.50 years  
                 
Weighted Average Discount Rate:                
Operating leases     4.75 %     4.75 %

 

Maturities of lease liabilities were as follows:

 

For the year ending December 31:      
2021 (excluding the six months ended June 30, 2021)   $ 348,710  
2022     710,186  
2023     724,391  
Total lease payments     1,783,287  
Less: imputed interest     (99,119 )
Total lease liabilities     1,684,168  
Less: current portion     (639,726 )
Lease liabilities – non-current portion   $ 1,044,442  

 

10. RELATED PARTY TRANSACTIONS

 

Accounts receivable

 

As of June 30, 2021, the Company had accounts receivable from Aixin Life Beauty, an entity controlled by the same major shareholder of the Company, of $6,020.

 

As of December 31, 2020, the Company had accounts receivable from a sales manager of Chengdu AiXinZhonghong Biological Technology Co., Ltd. (“AiXinZhonghong”), a Chinese limited company and a related party of the Company, of $60,262.

 

Due to related parties

 

Due to related parties consisted of the following as of the periods indicated:

 

    June 30,     December 31,  
    2021     2020  
Quanzhong Lin (major shareholder and Chairman of the Company)   $ 1,393,132     $ 1,027,305  
Aixin Life Beauty*     -       54,305  
Yirong Shen (major shareholder)     34,074       33,716  
Total   $ 1,427,206     $ 1,115,326  

 

* Entity controlled by Quanzhong Lin

 

The balances of due to related parties are payable on demand and bear no interest.

 

 

 

 

11. INCOME TAXES

 

PRC

 

The Company is governed by the Income Tax Laws of the PRC and various local tax laws. Effective January 1, 2008, China adopted a uniform tax rate of 25% for all enterprises (including foreign-invested enterprises).

 

The following table reconciles the PRC statutory rates to the Company’s effective tax rate for three months ended June 30, 2021 and 2020:

 

   

For the Three Months

Ended June 30,

 
    2021     2020  
Income tax (benefit) at PRC statutory rate     (25.0 )%     (25.0 )%
Change in deferred tax asset valuation allowance     25.0 %     25.0 %
Effective combined tax rate     - %     - %

 

The following table reconciles the PRC statutory rates to the Company’s effective tax rate for six months ended June 30, 2021 and 2020:

 

   

For the Six Months

Ended June 30,

 
    2021     2020  
Income tax (benefit) at PRC statutory rate     (25.0 )%     (25.0 )%
Change in deferred tax asset valuation allowance     25.0 %     25.0 %
Effective combined tax rate     - %     - %

 

For the three and six months ended June 30, 2021 and 2020, the change in valuation allowance is mainly from the tax benefit on net operating loss carry forward for PRC operations.

 

12. STATUTORY RESERVES

 

Pursuant to the PRC corporate law, the Company is now only required to maintain one statutory reserve by appropriating from its after-tax profit before declaration or payment of dividends. The statutory reserve represents restricted retained earnings.

 

Surplus reserve fund

 

The Company is now required to transfer 10% of its net income, as determined under PRC accounting rules and regulations, to a statutory surplus reserve fund until such reserve balance reaches 50% of the Company’s registered capital. During the three and six months ended June 30, 2021 and 2020, the Company made no contribution to its statutory reserve fund due to its accumulated deficit.

 

The surplus reserve fund is non-distributable other than during liquidation and can be used to fund previous years’ losses, if any, and may be utilized for business expansion or converted into share capital by issuing new shares to existing shareholders in proportion to their shareholding or by increasing the par value of the shares currently held by them, provided that the remaining reserve balance after such issue is not less than 25% of the registered capital.

 

 

 

 

Common welfare fund

 

Common welfare fund is a voluntary fund to which the Company can elect to transfer 5% to 10% of its net income, as determined under PRC accounting rules and regulations. The Company did not make any contribution to this fund during the three and six months ended June 30, 2021 and 2020.

 

This fund can only be utilized on capital items for the collective benefit of the Company’s employees, such as construction of dormitories, cafeteria facilities, and other staff welfare facilities. This fund is non-distributable other than upon liquidation.

 

13. OPERATING CONTINGENCIES

 

The Company’s operations in the PRC are subject to specific considerations and significant risks not typically associated with companies in North America and Western Europe. These include risks associated with, among others, the political, economic and legal environments and foreign currency exchange. The Company’s results may be adversely affected by changes in governmental policies with respect to laws and regulations, anti-inflationary measures, currency conversion and remittance abroad, and rates and methods of taxation, among other things.

 

The Company’s sales, purchases and expenses are denominated in RMB and all of the Company’s assets and liabilities are also denominated in RMB. The RMB is not freely convertible into foreign currencies under the current law. In China, foreign exchange transactions are required by law to be transacted only by authorized financial institutions. Remittances in currencies other than RMB may require certain supporting documentation to affect the remittance.

 

The Company is, from time to time, involved in litigation incidental to the conduct of its business regarding merchandise and services sold, employment matters, and litigation regarding intellectual property rights.

 

The Company believes that current pending litigation will not have a material adverse effect on its financial position, results of operations or cash flows.

 

14. SUBSEQUENT EVENT

 

In July, 2021, management completed the required governmental procedures and obtained the documents necessary to consider the equity transfer of Shangyan Hotel completed (see Note 1).

 

Management has evaluated subsequent events through the date which the financial statements were available to be issued. All subsequent events requiring recognition as of June 30, 2021 have been incorporated into these financial statements and there are no other subsequent events that require disclosure in accordance with FASB ASC Topic 855, “Subsequent Events.”

 

 

 

 

Exhibit 99.4

 

CHENGDU AIXINTANG PHARMACY CO., LTD AND AFFILIATES

COMBINED BALANCE SHEETS

 

    June 30,     December 31,  
    2021     2020  
    (Unaudited)        
ASSETS                
CURRENT ASSETS                
Cash and cash equivalents   $ 80,148     $ 80,319  
Accounts receivable, net     23,968       20,849  
Advance to suppliers     5,238       2,318  
Other receivables and prepaid expense     90,722       76,408  
Inventory, net     113,541       109,808  
Total current assets     313,617       289,702  
NON-CURRENT ASSETS                
Property and equipment, net     5,224       7,930  
Operating lease right-of-use assets     436,923       270,432  
Total non-current assets     442,147       278,362  
TOTAL ASSETS   $ 755,764     $ 568,064  
                 
LIABILITIES AND STOCKHOLDERS’ DEFICIT                
CURRENT LIABILITIES                
Accounts payable   $ 79,013     $ 68,587  
Accrued liabilities and other payables     53,491       54,270  
Due to related parties     1,452,597       1,161,699  
Taxes payable     -       246  
Operating lease liabilities - current     154,631       104,234  
Total current liabilities     1,739,732       1,389,036  
NON-CURRENT LIABILITIES                
Operating lease liabilities - non-current     282,292       166,198  
Total non-current liabilities     282,292       166,198  
TOTAL LIABILITIES     2,022,024       1,555,234  
STOCKHOLDERS’ DEFICIT                
Paid-in capital     249,399       249,399  
Accumulated deficit     (1,460,696 )     (1,192,623 )
Accumulated other comprehensive loss     (54,963 )     (43,946 )
Total stockholders’ deficit     (1,266,260 )     (987,170 )
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT   $ 755,764     $ 568,064  

 

 

 

 

CHENGDU AIXINTANG PHARMACY CO., LTD AND AFFILIATES

COMBINED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(UNAUDITED)

 

   

For the Three Months Ended June 30,

   

For The Six Months Ended June 30,

 
    2021     2020     2021     2020  
Revenue, net   $ 158,297     $ 299,403     $ 303,000     $ 959,191  
Cost of revenue     112,002       226,589       215,307       818,089  
Gross profit     46,295       72,814       87,693       141,102  
                                 
Operating expense                                
Selling expenses     140,965       121,538       283,382       206,637  
General and administrative expenses     31,555       18,645       75,224       38,677  
Total operating expenses     172,520       140,183       358,606       245,314  
                                 
Loss from operations     (126,225 )     (67,369 )     (270,913 )     (104,212 )
                                 
Other income (expenses)                                
Other income     1,620       1,772       2,785       3,872  
Interest income     36       27       86       41  
Other expenses     (32 )     4,654       (32 )     (2,069 )
Interest expense     1       -       1       (9 )
Total other income, net     1,625       6,453       2,840       1,835  
                                 
Loss before income tax     (124,600 )     (60,916 )     (268,073 )     (102,377 )
Income tax     -       -       -       28  
Net loss     (124,600 )     (60,916 )     (268,073 )     (102,405 )
                                 
Other comprehensive items                                
Foreign currency translation income (loss)     (16,592 )     (62,999 )     (11,017 )     9,369  
Comprehensive loss   $ (141,192 )   $ (123,915 )   $ (279,090 )   $ (93,036 )

 

 

 

 

CHENGDU AIXINTANG PHARMACY CO., LTD AND AFFILIATES

COMBINED STATEMENTS OF CHANGES IN EQUITY

(UNAUDITED)

 

                Accumulated        
          Accumulated     Other Comprehensive        
    Paid in capital     Deficit     Loss     Total  
Balance at December 31, 2020   $ 249,399     $ (1,192,623 )   $ (43,946 )   $ (987,170 )
Net loss     -       (143,473 )     -       (143,473 )
Foreign currency translation     -       -       5,575       5,575  
Balance at March 31, 2021     249,399       (1,336,096 )     (38,371 )     (1,125,068 )
Net loss     -       (124,600 )     -       (124,600 )
Foreign currency translation     -       -       (16,592 )     (16,592 )
Balance at June 30, 2021   $ 249,399     $ (1,460,696 )   $ (54,963 )   $ (1,266,260 )

 

                Accumulated        
          Accumulated     Other Comprehensive        
    Paid in capital     Deficit     Income     Total  
Balance at December 31, 2019   $ 189,760     $ (975,650 )   $ 18,408     $ (767,482 )
Net loss     -       (41,489 )     -       (41,489 )
Foreign currency translation     -       -       72,368       72,368  
Balance at March 31, 2020     189,760       (1,017,139 )     90,776       (736,603 )
Net loss     -       (60,916 )     -       (60,916 )
Acquisition of affiliate company     59,639       (31,556 )     -       28,083  
Foreign currency translation     -       -       (62,999 )     (62,999 )
Balance at June 30, 2020   $ 249,399     $ (1,109,611 )   $ 27,777     $ (832,435 )

 

 

 

 

CHENGDU AIXINTANG PHARMACY CO., LTD AND AFFILIATES

COMBINED STATEMENTS OF CASH FLOWS

(UNAUDITED)

 

    For The Six Months Ended June 30,  
    2021     2020  
Cash flows from operating activities                
Net loss   $ (268,073 )   $ (102,405 )
Adjustments to reconcile net loss to net cash used in operating activities:                
Depreciation     2,785       978  
Changes in assets and liabilities:                
Accounts receivable     (2,891 )     (2,837 )
Advance to suppliers     (2,890 )     (761,251 )
Other receivables     (5,663 )     (37,094 )
Inventory     (2,563 )     (16,823 )
Prepaid expenses and other current assets     (7,813 )     23,924  
Accounts payable     9,680       696,468  
Accrued expenses and other current liabilities     (1,350 )     121,229  
Taxes Payable     (248 )     -  
Net cash used in operating activities     (279,026 )     (77,811 )
                 
Cash flows from investing activities                
Purchase of equipment     -       (961 )
Acquisition of affiliate equity interest, net of cash acquired     -       6,635  
Net cash provided by investing activities     -       5,674  
                 
Cash flows from financing activities                
Net proceeds from related parties     278,007       106,065  
Net cash provided by financing activities     278,007       106,065  
                 
Effect of exchange rate changes on cash and cash equivalents     848       (470 )
                 
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS     (171 )     33,458  
                 
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD     80,319       21,371  
                 
CASH AND CASH EQUIVALENTS, END OF PERIOD   $ 80,148     $ 54,829  
                 
Supplemental cash flow data:                
Income tax paid   $ -     $ -  
Interest paid   $ -     $ -  

 

 

 

 

CHENGDU AIXINTANG PHARMACY CO., LTD AND AFFILIATES

NOTES TO COMBINED FINANCIAL STATEMENTS

(UNAUDITED)

 

1. ORGANIZATION AND DESCRIPTION OF BUSINESS

 

Chengdu Aixintang Pharmacy Co., Ltd and its branches and affiliates, totaled nine pharmacies (the “Company” or “Aixintang Pharmacies”), were legally registered and have been validly existing in Chengdu, Mianyang and other cities of Sichuan Province in the PRC since 2016. Each of the pharmacies engages in the retail sale of pharmaceuticals; sales of pre-packaged food and bulk food, health food, dairy products, cosmetics, electronic products, disinfecting supplies, class-I, and class-II medical equipment and the staff at each pharmacy consults with customers regarding common nutrition and health issues, though they are not licensed to make a diagnosis and when appropriate refer customers to a physician.

 

On June 2, 2021, HK Aixin International Group Co., Limited (“HK Aixin”), a wholly owned subsidiary of Aixin Life International, Inc. (“Aixin Life”), entered into an Equity Transfer Agreement (the “Transfer Agreement”) with Quanzhong Lin, Ting Li, and Xiao Ling Li, the three shareholders of Aixintang Pharmacies. Mr. Quanzhong Lin, who is also the major shareholder, Chairman and President of Aixin Life, owns in excess of 95% of the outstanding equity of Aixintang Pharmacies. The remaining equity interest is owned by Ting Li and Xiao Ling Li. Under the terms of the Transfer Agreement, HK Aixin agreed to purchase all of the outstanding equity of Aixintang Pharmacies for an aggregate purchase price of RMB 34,635,845 or US$5,308,257 based on an exchange rate of RMB/ US$ 6.5249 yuan per dollar on December 31, 2020. The purchase price will be reduced by an amount equal to any amounts paid or distributed by any of the Aixintang Pharmacies to Mr. Quanzhong Lin, Ting Li, or Xiao Ling Li after December 31, 2020 and increased by an amount equal to any amounts they contributed to any of the Aixintang Pharmacies after such date.

 

As of June 30, 2021, the governmental procedures to complete the equity transfer of Aixintang Pharmacies were not yet completed (see Note 12).

 

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of Presentation

 

The accompanying combined financial statements are prepared in conformity with U.S. Generally Accepted Accounting Principles (“US GAAP”). The functional currency of the Company is Chinese Renminbi (“RMB”). The accompanying financial statements are translated from RMB and presented in U.S. dollars (“USD”).

 

Covid – 19

 

On March 11, 2020, the World Health Organization announced that infections caused by the corona virus disease of 2019 (“COVID-19”) had become pandemic. The Government of China has adopted various regulations and orders, including mandatory quarantines, limits on the number of people that may gather in one location, closing non-essential businesses and travel bans to limit the spread of the disease. Many of these measures have been relaxed due to the decrease in the prevalence of Covid-19 in China. To date, the ongoing operations of the Company have not been materially adversely affected by the measures taken to limit the spread of the disease in China.

 

Financial impacts related to COVID-19, including the Company’s actions and costs incurred in response to the pandemic, were not material to the Company’s financial position, results of operations or cash flows for the three and six months ended June 30, 2021. The Company has implemented procedures to promote employee and customer safety. These measures will not significantly increase its operating costs.

 

While the Company continues to operate substantially in the normal course, it cannot forecast with any certainty whether and to what degree the disruptions caused by the COVID-19 pandemic will increase, or the extent to which the disruption may materially impact its financial position, results of operations, and cash flows in fiscal 2021.

 

 

 

 

Basis of Combination

 

The combined financial statements include the accounts of Chengdu Aixintang Pharmacy Co., Ltd and its affiliates, including Chengdu Beibang Pharmacy, Co., Ltd., Chengdu Xindu District Cundetang Pharmacy Co., Ltd., Chengdu Aixintang Liucheng Pharmacy Co., Ltd., Chengdu Wenjiang Aixinhui Pharmacy Co., Ltd., and Qionglai Weide Pharmacy. These companies are under common control and ownership. All significant intercompany accounts and transactions are eliminated.

 

Use of Estimates

 

In preparing combined financial statements in conformity with US GAAP, management makes estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the dates of the combined financial statements, as well as the reported amounts of revenues and expenses during the reporting period.

 

Significant estimates, required by management, include the recoverability of long-lived assets, allowance for doubtful accounts, and the reserve for obsolete and slow-moving inventories. Actual results could differ from those estimates.

 

Cash and Cash Equivalents

 

For financial statement purposes, the Company considers all highly liquid investments with an original maturity of three months or less to be cash and cash equivalents.

 

Accounts Receivable

 

Accounts receivable mainly consist of amounts due from the Social Security Bureau and Health Care Administration governed by local government. The Company’s policy is to maintain an allowance for potential credit losses on accounts receivable. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentrations, customer credit worthiness, current economic trends and changes in customer payment patterns to evaluate the adequacy of these reserves. As of June 30, 2021 and December 31, 2020, there was no bad debt allowance.

 

Inventory

 

Inventories are valued at the lower of cost or net realizable value using the weighted average cost method. Physical inventory counts are taken on a regular basis in each retail store. Management compares the cost of inventories with the net realizable value and an allowance is made for writing down inventories to market value, if lower. The Company recorded no inventory impairment for the three and six months ended June 30, 2021 and 2020.

 

Property and Equipment

 

Property and equipment are stated at cost, less accumulated depreciation, and impairment losses, if any. Major repairs and betterments that significantly extend original useful lives or improve productivity are capitalized and depreciated over the period benefited. Maintenance and repairs are expensed as incurred. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of property and equipment is provided using the straight-line method for substantially all assets with 5% salvage value and estimated lives as follows:

 

Furniture and Equipment

2~5 years

 

Impairment of Long-Lived Assets

 

Long-lived assets, which include property and equipment and intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable, but at least annually.

 

 

 

 

Recoverability of long-lived assets to be held and used is measured by comparing the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by it. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds its fair value. Fair value is generally determined using the asset’s expected future discounted cash flows or market value, if readily determinable. Based on its review, the Company believes that, as of June 30, 2021 and December 31, 2020, there were no significant impairments of its long-lived assets.

 

Income Taxes

 

Income taxes are accounted for using an asset and liability method. Under this method, deferred income taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts at each period end based on enacted tax laws and statutory tax rates, applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.

 

The Company follows Accounting Standards Codification (“ASC”) Topic 740, which prescribes a more-likely-than-not threshold for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. ASC Topic 740 also provides guidance on recognition of income tax assets and liabilities, classification of current and deferred income tax assets and liabilities, accounting for interest and penalties associated with tax positions, accounting for income taxes in interim periods, and income tax disclosures.

 

Under ASC Topic 740, when tax returns are filed, it is likely that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained. The benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50% likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described above is reflected as a liability for unrecognized tax benefits in the accompanying balance sheets along with any associated interest and penalties that would be payable to the taxing authorities upon examination. Interest associated with unrecognized tax benefits is classified as interest expense and penalties are classified in selling, general and administrative expenses in the statement of income.

 

At June 30, 2021 and December 31, 2020, the Company did not take any uncertain positions that would necessitate recording a tax related liability.

 

Revenue Recognition

 

In accordance with ASC 606, revenue is recognized upon the transfer of control of promised goods or services to customers in an amount that reflects the consideration the Company expects to receive in exchange for those products or services.

 

Revenue from sale of goods under Topic 606 is recognized in a manner that reasonably reflects the delivery of the Company’s products and services to customers in return for expected consideration and includes the following elements:

 

  executed contract(s) with customers that the Company believes is legally enforceable;
     
  identification of performance obligation in the respective contract;
     
  determination of the transaction price for each performance obligation in the respective contract;
     
  allocation of the transaction price to each performance obligation; and
     
  recognition of revenue only when the Company satisfies each performance obligation.

 

The Company’s retail drugstores recognize revenue at the time the customer takes possession of the merchandise. For pharmacy sales, each prescription claim is its own arrangement with the customer and is a performance obligation.

 

 

 

 

The Company generally receives payments from customers as it satisfies its performance obligations. The Company records a receivable when it has an unconditional right to receive payment and only the passage of time is required before payment is due.

 

Sales revenue represents the invoiced value of goods, net of value-added taxes (“VAT”). All of the Company’s products sold in China are subject to the PRC VAT of 0% as the Company qualifies for small businesses. The VAT may be offset by VAT paid by the Company on inventories and products purchased in China. The Company records VAT payable and VAT receivable net of payments in the financial statements. The VAT tax return is filed offsetting the payables against the receivables. Sales and purchases are recorded net of VAT collected and paid as the Company acts as an agent for the government.

 

Cost of Revenue

 

Cost of revenue consists primarily of the cost of products sold during the reporting period. Reserve for inventory allowance due to lower of cost or market is also recorded in cost of goods sold.

 

Concentration of Credit Risk

 

The operations of the Company are in the PRC. Accordingly, the Company’s business, financial condition, and results of operations may be influenced by the political, economic, and legal environments in the PRC, and by the general state of the PRC economy.

 

The Company has cash on hand and demand deposits in accounts maintained with state-owned banks within the PRC. Cash in state-owned banks is covered by insurance up to RMB 500,000 ($72,500) per bank. The Company has not experienced any losses in such accounts and believes they are not exposed to any risks on its cash in these bank accounts.

 

Leases

 

ASC Topic 842, “Leases,” requires recognition of leases on the combined balance sheets as right-of-use (“ROU”) assets and lease liabilities. ROU assets represent the Company’s right to use underlying assets for the lease terms and lease liabilities represent the Company’s obligation to make lease payments arising from the leases. Operating lease ROU assets and operating lease liabilities are recognized based on the present value and future minimum lease payments over the lease term at commencement date. The Company’s future minimum based payments used to determine the Company’s lease liabilities mainly include minimum based rent payments. As most of the Company’s leases do not provide an implicit rate, the Company uses its estimated incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments.

 

Operating lease cost is recognized as a single lease cost on a straight-line basis over the lease term and is recorded in selling, general and administrative expenses. Variable lease payments for common area maintenance, property taxes and other operating expenses are recognized as expense in the period when the changes in facts and circumstances on which the variable lease payments are based occur.

 

Statement of Cash Flows

 

In accordance with ASC Topic 230, “Statement of Cash Flows,” cash flows from the Company’s operations are calculated based on the local currencies using the average translation rates. As a result, amounts related to assets and liabilities reported on the combined statements of cash flows will not necessarily agree with changes in the corresponding balances on the balance sheets.

 

Fair Value of Financial Instruments

 

The carrying amounts of certain of the Company’s financial instruments, including cash and equivalents, accrued liabilities and accounts payable, approximate their fair value due to their short maturities. FASB ASC Topic 825, “Financial Instruments,” requires disclosure of the fair value of financial instruments held by the Company. The carrying amounts reported in the balance sheets for current liabilities each qualify as financial instruments and are a reasonable estimate of their fair value because of the short period of time between the origination of such instruments and their expected realization and the current market rate of interest.

 

 

 

 

Fair Value Measurements and Disclosures

 

ASC Topic 820, “Fair Value Measurements and Disclosures,” defines fair value, and establishes a three-level valuation hierarchy for disclosures of fair value measurement that enhances disclosure requirements for fair value measures. The three levels are defined as follow:

 

  Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.
  Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.
  Level 3 inputs to the valuation methodology are unobservable and significant to the fair value measurement.

 

As of June 30, 2021 and December 31, 2020, the Company did not identify any assets and liabilities that are required to be presented on the balance sheet at fair value.

 

Foreign Currency Translation and Comprehensive Income (Loss)

 

The functional currency of the Company is RMB. For financial reporting purposes, RMB is translated into USD as the reporting currency. Assets and liabilities are translated at the exchange rate in effect at the balance sheet dates. Revenues and expenses are translated at the average rate of exchange prevailing during the reporting period.

 

Translation adjustments arising from the use of different exchange rates from period to period are included as a component of stockholders’ equity as “Accumulated other comprehensive income”. Gains and losses resulting from foreign currency transactions are included in income. There was no significant fluctuation in the exchange rate for the conversion of RMB to USD after the balance sheet date.

 

The Company uses FASB ASC Topic 220, “Comprehensive Income”. Comprehensive loss is comprised of net loss and all changes to the statements of stockholders’ equity, except those due to investments by stockholders, changes in paid-in capital and distributions to stockholders. Comprehensive income (loss) for the three and six months ended June 30, 2021 and 2020 consisted of net income (loss) and foreign currency translation adjustments.

 

Earnings per Share

 

The Company is a limited Company (“LC”) formed under the laws of the PRC. Like limited liability company in the US, limited company in the PRC do not issue shares to the owners. The owners however, are called shareholders. Ownership interest is determined in proportion to capital contributed. Accordingly, earnings per share data is not presented.

 

Segment Reporting

 

ASC Topic 280, “Segment Reporting,” requires use of the “management approach” model for segment reporting. The management approach model is based on the way a company’s chief operating decision maker organizes segments within the Company for making operating decisions assessing performance and allocating resources. Reportable segments are based on products and services, geography, legal structure, management structure, or any other manner in which management disaggregates a company.

 

Management determined the Company’s operations constitute a single reportable segment in accordance with ASC 280. The Company operates exclusively in one business and industry segment: retail pharmacy.

 

New Accounting Pronouncements

 

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326), which requires entities to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. This replaces the existing incurred loss model and is applicable to the measurement of credit losses on financial assets measured at amortized cost. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2022. Early application will be permitted for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. The Company is currently evaluating the impact that the standard will have on its financial statements.

 

 

 

 

In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848) (“ASU 2020-04”). ASU 2020-04 contains practical expedients for reference rate reform related activities that impact debt, leases, derivatives and other contracts. The guidance in ASU 2020-04 is optional and may be elected over time as reference rate reform activities occur. The Company continues to evaluate the impact of the guidance and may apply the elections as applicable as changes in the market occur.

 

3. OTHER RECEIVABLES AND PREPAID EXPENSES

 

The Company had other receivables and prepaid expenses of $90,722 and $76,408 as of June 30, 2021 and December 31, 2020, respectively. Prepaid expenses primarily consist of rent and other services to be expensed over the contracted period.

 

4. INVENTORY

 

Inventory consisted of the following at June 30, 2021 and December 31, 2020:

 

    June 30, 2021     December 31, 2020  
Drugs, pharmaceutical and nutritional products   $ 113,541     $ 109,808  

 

5. PROPERTY AND EQUIPMENT, NET

 

Property and equipment consisted of the following at June 30, 2021 and December 31, 2020:

 

    June 30, 2021     December 31, 2020  
Furniture and office equipment   $ 14,450     $ 14,298  
Less: Accumulated depreciation     (9,226 )     (6,368 )
Property and equipment, net   $ 5,224     $ 7,930  

 

Depreciation expense for the three months ended June 30, 2021 and 2020 was $1,395 and $891, respectively. Depreciation expense for the six months ended June 30, 2021 and 2020 was $2,785 and $978, respectively.

 

6. ACCRUED LIABILITIES AND OTHER PAYABLES

 

Accrued liabilities and other payables consisted of the following at June 30, 2021 and December 31, 2020:

 

    June 30, 2021     December 31, 2020  
Accrued payroll   $ 50,065     $ 17,780  
Other payables     3,426       36,490  
Total   $ 53,491     $ 54,270  

 

7. LEASE

 

The Company leases its retail pharmacy stores under operating lease arrangements, typically with initial terms of 2 to 5 years.

 

Balance sheet information related to the Company’s leases is presented below:

 

    June 30, 2021     December 31, 2020  
Operating Leases                
Operating lease right-of-use assets   $ 436,923     $ 270,432  
                 
Operating lease liabilities - current   $ 154,631     $ 104,234  
Operating lease liabilities – non-current     282,292       166,198  
Total operating lease liabilities   $ 436,923     $ 270,432  

 

 

 

 

The following provides details of the Company’s lease expenses:

 

    Three Months Ended June 30,  
    2021     2020  
Operating lease expenses   $ 31,283     $ 36,355  

 

 

    Six Months Ended June 30,  
    2021     2020  
Operating lease expenses   $ 74,764     $ 73,613  

 

Other information related to leases is presented below:

 

    Six Months Ended June 30,  
    2021     2020  
Cash Paid For Amounts Included In Measurement of Liabilities:                
Operating cash flows from operating leases   $ 74,764     $ 73,613  
                 
Weighted Average Remaining Lease Term:                
Operating leases     3.00 years       2.81 years  
                 
Weighted Average Discount Rate:                
Operating leases     4.75 %     4.75 %

 

Maturities of lease liabilities were as follows:

 

For the year ending December 31,      
2021 (excluding the six months ended June 30, 2021)   $ 85,475  
2022     174,271  
2023     150,072  
2024     36,015  
2025     14,762  
Thereafter     6,275  
Total lease payments     466,870  
Less: imputed interest     (29,947 )
Total lease liabilities     436,923  
Less: current portion     (154,631 )
Lease liabilities – non-current portion   $ 282,292  

 

8. RELATED PARTY TRANSACTIONS

 

Due to related parties are unsecured, bear no interest and payable upon demand.

 

Due to related parties

 

    June 30, 2021     December 31, 2020  
Quanzhong Lin   $ 1,441,753     $ 1,109,376  
Branch manager     -       28,602  
Chengdu Aixin Zhonghong Biological Technology Co., Ltd. (“Aixin Zhonghong”)     -       12,991  
Chengdu Aixin E-Commence Co., Ltd.     9,417       9,318  
Chengdu Aixin International Travel Service Co., Ltd.     1,427       1,412  
Total   $ 1,452,597     $ 1,161,699  

 

 

 

 

Mr. Quanzhong Lin is the major shareholder and Chairman of Aixintang Pharmacies. All of the related party entities are controlled by Mr. Quanzhong Lin. The advances are for working capital purpose, payable on demand and bear no interest.

 

The balances due to one branch manager were for working capital purpose, payable on demand and bear no interest.

 

9. INCOME TAXES

 

The Company is governed by the Income Tax Laws of the PRC and various local tax laws. Effective January 1, 2008, China adopted a uniform tax rate of 25% for all enterprises (including foreign-invested enterprises).

 

The following table reconciles the PRC statutory rates to the Company’s effective tax rate for three months ended June 30, 2021 and 2020:

 

    Three Months Ended June 30,  
    2021     2020  
Income tax (benefit) at PRC statutory rate     (25.0 )%     (25.0 )%
Change in deferred tax asset valuation allowance     25.0 %     25.0 %
Other     - %     - %
Effective combined tax rate     - %     - %

 

The following table reconciles the PRC statutory rates to the Company’s effective tax rate for six months ended June 30, 2021 and 2020:

 

    Six Months Ended June 30,  
    2021     2020  
Income tax (benefit) at PRC statutory rate     (25.0 )%     (25.0 )%
Change in deferred tax asset valuation allowance     25.0 %     25.0 %
Other     - %     0.03 %
Effective combined tax rate     - %     0.03 %

 

For the three and six months ended June 30, 2021 and 2020, the change in valuation allowance is mainly from the tax benefit on net operating loss carry forward for PRC operations.

 

10. STATUTORY RESERVES

 

Pursuant to the PRC corporate law, the Company is now only required to maintain one statutory reserve by appropriating from its after-tax profit before declaration or payment of dividends. The statutory reserve represents restricted retained earnings.

 

Surplus reserve fund

 

The Company is now required to transfer 10% of its net income, as determined under PRC accounting rules and regulations, to a statutory surplus reserve fund until such reserve balance reaches 50% of the Company’s registered capital. During the three and six months ended June 30, 2021 and 2020, the Company made $0 to its statutory reserve fund due to its accumulated deficit.

 

The surplus reserve fund is non-distributable other than during liquidation and can be used to fund previous years’ losses, if any, and may be utilized for business expansion or converted into share capital by issuing new shares to existing shareholders in proportion to their shareholding or by increasing the par value of the shares currently held by them, provided that the remaining reserve balance after such issue is not less than 25% of the registered capital.

 

 

 

 

Common welfare fund

 

Common welfare fund is a voluntary fund to which the Company can elect to transfer 5% to 10% of its net income, as determined under PRC accounting rules and regulations. The Company did not make any contribution to this fund during the three and six months ended June 30, 2021 and 2020.

 

This fund can only be utilized on capital items for the collective benefit of the Company’s employees, such as construction of dormitories, cafeteria facilities, and other staff welfare facilities. This fund is non-distributable other than upon liquidation.

 

11. OPERATING CONTINGENCIES

 

The Company’s operations in the PRC are subject to specific considerations and significant risks not typically associated with companies in North America and Western Europe. These include risks associated with, among others, the political, economic and legal environments and foreign currency exchange. The Company’s results may be adversely affected by changes in governmental policies with respect to laws and regulations, anti-inflationary measures, currency conversion and remittance abroad, and rates and methods of taxation, among other things.

 

The Company’s sales, purchases and expenses are denominated in RMB and all of the Company’s assets and liabilities are also denominated in RMB. The RMB is not freely convertible into foreign currencies under the current law. In China, foreign exchange transactions are required by law to be transacted only by authorized financial institutions. Remittances in currencies other than RMB may require certain supporting documentation to affect the remittance.

 

The Company is, from time to time, involved in litigation incidental to the conduct of its business regarding merchandise sold, employment matters, and litigation regarding intellectual property rights.

 

The Company believes that current pending litigation will not have a material adverse effect on its financial position, results of operations or cash flows.

 

12. SUBSEQUENT EVENT

 

In August and September, 2021, management completed the required governmental procedures and obtained the documents necessary to consider the equity transfer of Aixintang Pharmacies completed (see Note 1).

 

Management has evaluated subsequent events through the date which the financial statements were available to be issued. All subsequent events requiring recognition as of June 30, 2021 have been incorporated into these financial statements and there are no other subsequent events that require disclosure in accordance with FASB ASC Topic 855, “Subsequent Events.”

 

 

 

 

Exhibit 99.5

 

AIXIN LIFE INTERNATIONAL, INC.

UNAUDITED PRO FORMA COMBINED BALANCE SHEET

AS OF JUNE 30, 2021

 

    AIXIN LIFE INTERNATIONAL, INC.     AIXINTANG PHARMACIES     AIXIN SHANGYAN HOTEL     PRO FORMA ADJUSTMENTS         PRO FORMA COMBINED  
                                   
ASSETS                                            
Current Assets                                            
Cash and cash equivalents   $ 3,248,619     $ 80,148     $ 19,039     $ (2,666,641 )   {b}   $ 681,165  
Accounts receivable, net     -       23,968       27,163                   51,131  
Accounts receivable, related party     -       -       6,020                   6,020  
Other receivables and prepaid expense     33,525       90,722       105,279                   229,526  
Advance to suppliers     271,130       5,238       -                   276,368  
Prepayment for acquisition     4,504,418       -       -       (4,504,418 )   {b}     -  
Advance to related parties     199,843       -       -                   199,843  
Inventory     135,066       113,541       184,739                   433,346  
Total Current Assets     8,392,601       313,617       342,240       (7,171,059 )         1,877,399  
Non-Current Assets                                            
Property and equipment, net     57,643       5,224       309,883                   372,750  
Intangible assets, net     -       -       3,213                   3,213  
Security deposits     -       -       92,928                   92,928  
Operating lease right-of-use assets     84,117       436,923       1,684,168                   2,205,208  
Total Non-Current Assets     141,760       442,147       2,090,192       --           2,674,099  
Total Assets   $ 8,534,361     $ 755,764     $ 2,432,432     $ (7,171,059 )       $ 4,551,498  
                                             
LIABILITIES AND STOCKHOLDERS’ EQUITY                                            
Current Liabilities                                            
Accounts payable   $ 39,531     $ 79,013     $ 284,498     $ (363,511 )   {a}   $ 39,531  
Unearned revenue     2,793       -       293,857       (293,857 )   {a}     2,793  
Taxes payable     239,341       -       4,138       (4,138 )   {a}     239,341  
Accrued liabilities and other payables     541,942       53,491       246,129       (299,620 )   {a}     541,942  
Loan from third parties     -       -       462,282       (462,282 )   {a}     -  
Operating lease liabilities - current     37,551       154,631       639,726                   831,908  
Advance from related parties     3,274       1,452,597       1,427,206       (2,879,803 )   {a}     3,274  
Total Current Liabilities     864,432       1,739,732       3,357,836       (4,303,211 )         1,658,789  
Non-Current Liabilities                                            
Operating lease liabilities - noncurrent     46,566       282,292       1,044,442                   1,373,300  
Total Non-Current Liabilities     46,566       282,292       1,044,442                   1,373,300  
Total Liabilities     910,998       2,022,024       4,402,278       (4,303,211 )         3,032,089  
Stockholders’ Equity                                            
Common stock     500       -       -                   500  
Additional paid in capital     11,301,535       249,399       152,207       (2,867,848 )   {a} {b}     8,835,293  
Statutory reserve     151,988       -       -                   151,988  
Accumulated deficit     (4,496,324 )     (1,460,696 )     (2,033,012 )                 (7,990,032 )
Accumulated other comprehensive income (loss)     665,664       (54,963 )     (89,041 )                 521,660  
Total Stockholders’ Equity     7,623,363       (1,266,260 )     (1,969,846 )     (2,867,848 )         1,519,409  
Total Liabilities and Stockholders’ Equity   $ 8,534,361     $ 755,764     $ 2,432,432     $ (7,171,059 )       $ 4,551,498  

 

See accompanying notes to pro forma combined financial statements

 

 

 

 

AIXIN LIFE INTERNATIONAL, INC.

UNAUDITED PRO FORMA COMBINED STATEMENT OF OPERATIONS AND COMPREHENSIVE LOSS

FOR THE SIX MONTHS ENDED JUNE 30, 2021

 

    AIXIN LIFE INTERNATIONAL, INC.     AIXINTANG PHARMACIES     AIXIN SHANGYAN HOTEL     PRO FORMA ADJUSTMENTS     PRO FORMA COMBINED  
                               
Revenue                                        
Products   $ 253,245     $ -     $ -                   $ 253,245  
Advertising     1,297,681       -       -               1,297,681  
Pharmacy revenue     -       303,000       -               303,000  
Hotel revenue     -       -       748,056               748,056  
Total revenues, net     1,550,926       303,000       748,056               2,601,982  
                                         
Operating costs and expenses:                                        
Cost of goods sold     160,680       215,307       -               375,987  
Hotel operating costs     -       -       1,043,851               1,043,851  
Selling expenses     93,881       283,382       74,189               451,452  
General and administrative expenses     419,921       75,224       164,038               659,183  
Stock-based compensation     185,770       -       -               185,770  
Total operating costs and expenses     860,252       573,913       1,282,078               2,716,243  
                                         
Income (loss) from operations     690,674       (270,913 )     (534,022 )             (114,261 )
                                         
Non-operating income (expenses)                                        
Interest income     2,489       86       21               2,596  
Other income     161       2,785       52,548               55,494  
Other expenses     (6,885 )     (31 )                     (6,916 )
Total non-operating income (expenses), net     (4,235 )     2,840       52,569               51,174  
                                         
Income (loss) before income tax     686,439       (268,073 )     (481,453 )             (63,087 )
                                         
Income tax expense     218,052       -                       218,052  
                                         
Net income (loss)     468,387       (268,073 )     (481,453 )             (281,139 )
                                         
Other comprehensive items Foreign currency translation (loss)     77,124       (11,017 )     (16,604 )             49,503  
                                         
Comprehensive income (loss)   $ 545,511     $ (279,090 )   $ (498,057 )           $ (231,636 )
                                         
Income (loss) per share   $ 0.009     $ -     $ -             $ (0.006 )
                                         
Weighted average shares outstanding     49,999,891       -       -               49,999,891  

 

 

See accompanying notes to pro forma combined financial statements

 

 

 

 

AIXIN LIFE INTERNATIONAL, INC.

UNAUDITED PRO FORMA COMBINED STATEMENT OF OPERATIONS AND COMPREHENSIVE LOSS

FOR THE YEAR ENDED DECEMBER 31, 2020

 

    AIXIN LIFE INTERNATIONAL, INC.     AIXINTANG PHARMACIES     AIXIN SHANGYAN HOTEL     PRO FORMA ADJUSTMENTS     PRO FORMA COMBINED  
                               
Revenue                                        
Products   $ 580,712     $ -     $ -                  $ 580,712  
Advertising     1,870,343       -       -               1,870,343  
Pharmacy revenue     -       1,264,427       -               1,264,427  
Hotel revenue     -       -       1,074,151               1,074,151  
Total revenues, net     2,451,055       1,264,427       1,074,151               4,789,633  
                                         
Operating costs and expenses:                                        
Cost of goods sold     224,675       933,081       -               1,157,756  
Hotel operating costs     -       -       1,537,307               1,537,307  
Selling expenses     244,200       435,348       116,564               796,112  
General and administrative expenses     802,556       84,359       164,466               1,051,381  
Provision for bad debts     13,624       -       22,227               35,851  
Stock-based compensation     371,540       -       -               371,540  
Total operating costs and expenses     1,656,595       1,452,788       1,840,564               4,949,947  
                                         
Income (loss) from operations     794,460       (188,361 )     (766,413 )             (160,314 )
                                         
Non-operating income (expenses)                                        
Interest income     537,580       120       31               537,731  
Interest expense     -       (8 )     -               (8 )
Other income     28,924       5,518       82,398               116,840  
Other expenses     (3,326 )     (2,658 )     (5,121 )             (11,105 )
Total non-operating income, net     563,178       2,972       77,308               643,458  
                                         
Income (loss) before income tax     1,357,638       (185,389 )     (689,105 )             483,144  
                                         
Income tax expense     340,127       28       -               340,155  
                                         
Net income (loss)     1,017,511       (185,417 )     (689,105 )             142,989  
                                         
Other comprehensive items Foreign currency translation (loss)     437,059       (62,354 )     (86,642 )             288,063  
                                         
Comprehensive income (loss)   $ 1,454,570     $ (247,771 )   $ (775,747 )           $ 431,052  
                                         
Income per share   $ 0.016     $ -     $ -             $ 0.002  
                                         
Weighted average shares outstanding     65,609,450       -       -               65,609,450  

 

See accompanying notes to pro forma combined financial statements

 

 

 

 

AIXIN LIFE INTERNATIONAL, INC.

NOTES TO UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS

 

NOTE 1 - INTRODUCTION

 

On June 2, 2021, HK Aixin International Group Co., Limited (“HK Aixin”), a wholly owned subsidiary of Aixin Life International, Inc (“Aixin Life” or the “Company”) entered into an Equity Transfer Agreement (the “Transfer Agreement”) with Quanzhong Lin, Ting Li, and Xiao Ling Li (the “Transferor”), the shareholders of Chengdu Aixintang Pharmacy Co., Ltd. and certain affiliated entities, each of which operates a pharmacy (“Aixintang Pharmacies”). Mr. Lin is the major shareholder, Chairman and President of Aixin Life. Mr. Lin also owns in excess of 95% of the outstanding equity the Aixintang Pharmacies. The remaining equity interest is owned by Ting Li and Xiao Ling Li. Pursuant to the Transfer Agreement, HK Aixin agreed to purchase all of the outstanding equity of Aixintang Pharmacies for an aggregate purchase price of RMB 34,635,845, or approximately US$5,308,257 (“Transfer Price”). The Transfer Price will be reduced by an amount equal to any amounts paid or distributed by any of the Aixintang Pharmacies to the Transferor after December 31, 2020 and increased by an amount contributed to any of the Aixintang Pharmacies by the Transferor after such date. The Transfer Price, as adjusted in accordance with this Section, is referred to as the “Adjusted Transfer Price.”

 

On May 25, 2021, Aixin Life International, Inc entered into an Equity Transfer Agreement with the two shareholders, Quanzhong Lin and Yirong Shen (the “Transferor”), of Chengdu Aixin Shangyan Hotel Management Co., Ltd (“Aixin Shangyan Hotel”). Quanzhong Lin is also the Chairman, President and major shareholder of Aixin Life. Pursuant to the Agreement (the “Hotel Purchase Agreement”), Aixin Life agreed to purchase 100% ownership of Aixin Shangyan Hotel from Mr. Lin and Ms. Shen. Eighty percent of the equity of Aixin Shangyan Hotel is owned by Mr. Lin. The balance is owned by Ms. Shen. Under the terms of the Hotel Purchase Agreement, Aixin Life agreed to purchase all of the outstanding equity of Aixin Shangyan Hotel for a purchase price of RMB 7,598,887, or approximately $1,164,598, (“Transfer Price”). The Transfer Price will be reduced by an amount equal to any amounts paid or distributed by Aixin Shangyan Hotel to Mr. Lin or Ms. Shen after December 31, 2020 and will be increased by an amount equal to any amounts they contributed to Aixin Shangyan Hotel after December 31, 2020. The Transfer Price, as adjusted in accordance with this Section, is referred to as the “Adjusted Transfer Price.”

 

NOTE 2 - BASIS OF PRESENTATION

 

The unaudited pro forma condensed combined balance sheet as of June 30, 2021 combines the historical balance sheets of Aixin Life, Aixintang Pharmacies, and Aixin Shangyan Hotel as if the Transactions had occurred on June 30, 2021. The unaudited pro forma combined statements of operations and comprehensive loss for the six months ended June 30, 2021 and for the year ended December 31, 2020 combine the historical consolidated statements of operations and comprehensive income (loss) of Aixin Life, Aixintang Pharmacies, and Aixin Shangyan Hotel, and have been prepared as if the Transactions had closed on January 1, 2020, respectively. The unaudited pro forma condensed combined financial statements have also been adjusted to give effect to pro forma events that are directly attributable to the Transactions, factually supportable and expected to have a continuing impact on the combined results.

 

The unaudited pro forma condensed combined financial information was prepared using the acquisition method of accounting in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 805, Business Combinations. Aixin Life, Aixintang Pharmacies, and Aixin Shangyan Hotel are under common control and ownership.

 

The preliminary unaudited pro forma information is presented solely for informational purposes and is not necessarily indicative of the consolidated results of operations or financial position that might have been achieved for the periods or dates indicated, nor is it necessarily indicative of the future results of the combined company.

 

NOTE 3 – PRO FORMA ADJUSTMENTS

 

The following adjustments were made in the preparation of the unaudited pro forma condensed consolidated combined balance sheet and unaudited pro forma condensed consolidated combined statements of income and comprehensive income:

 

{a} Pursuant to the Transfer Agreement and Hotel Purchase Agreement, the actual or potential creditor’s rights and debts of Aixintang Pharmacies and Aixin Shangyan Hotel prior to the date of equity transfer shall be owned and undertaken by the Transferor. After the transfer, the Transferor shall independently assume the liability for litigations or losses of Aixintang Pharmacies and Aixin Shangyan Hotel caused by the actual or potential debts prior to the date of equity transfer.

 

{b} Represents the proceeds made by Aixin Life based on the Adjusted Transfer Price. The Adjusted Transfer Price is based on the Transfer Price of $5,308,257, increased by $332,377 contributed to Aixintang Pharmacies by Mr. Lin during the six months ended June 30, 2021, and the Transfer Price of $1,164,598, increased by $365,827 contributed to Aixin Shangyan Hotel by Mr. Lin during the six months ended June 30, 2021. As of June 30, 2021, these two acquisitions have not yet been completed, and Aixin Life prepaid $4,504,418 for the acquisition price.